



THIRD-QUARTER 2023 RESULTS

TOTAL COMPANY

\$10.1B **13.8%**¹

SALES
WORLDWIDE

ORGANIC* SALES GROWTH
FOR UNDERLYING
BASE BUSINESS**

\$1.14²

ADJUSTED DILUTED EPS

**RAISING MIDPOINT
OF FULL-YEAR
EPS GUIDANCE RANGE**

\$4.42 to \$4.46³

Adjusted Diluted EPS

BUSINESS HIGHLIGHTS

MORE PEOPLE USING CGM AND GLP-1 DRUGS TOGETHER

- ▶ Newly published Abbott analysis shows growing number of people are using Abbott's FreeStyle Libre[®] continuous glucose monitoring systems and GLP-1 medications together.
- ▶ Abbott analysis also shows these complementary tools help support behavior change, diabetes treatment and overall health.



COMPLETED ACQUISITION OF BIGFOOT BIOMEDICAL

- ▶ Expands development of personalized solutions for diabetes management.
- ▶ Builds on Abbott's world-leading FreeStyle Libre portfolio of continuous glucose monitoring systems.



BROADENING EMERGING MARKET ACCESS TO CUTTING-EDGE MEDICINES

- ▶ Expanded existing collaboration with global biotech leader mAbxience Holdings S.L.
- ▶ Abbott will commercialize several biosimilar molecules, with the goal of broadening access to these therapies for people in emerging markets.



KEY BUSINESS UNITS⁴

ORGANIC* SALES GROWTH FOR UNDERLYING BASE BUSINESS**



14.7%

MEDICAL DEVICES



10.1%

DIAGNOSTICS



11.1%

ESTABLISHED
PHARMACEUTICALS



18.1%

NUTRITION

¹On a GAAP basis, third-quarter 2023 Abbott sales decreased 2.6%. ²Third-quarter GAAP diluted EPS was \$0.82. ³Abbott projects full-year 2023 diluted earnings per share from continuing operations under GAAP of \$3.14 to \$3.18. Abbott forecasts specified items for the full-year 2023 of \$1.28 per share primarily related to intangible amortization, costs associated with acquisitions, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be \$4.42 to \$4.46 for the full-year 2023. ⁴On a GAAP basis, Medical Devices sales increased 16.6%, Established Pharmaceuticals sales increased 3.2%, Diagnostics sales decreased 32.7%, and Nutrition sales increased 15.5%.

**Find important safety information about the FreeStyle Libre portfolio: www.freestylelibre.us/safety-information.

FORWARD-LOOKING STATEMENTS

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2022, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.